For research use only. Not for therapeutic Use.
Irpagratinib(CAT: I040871) is a selective inhibitor of fibroblast growth factor receptor (FGFR), specifically targeting FGFR1, FGFR2, and FGFR3. It works by blocking the FGFR signaling pathway, which plays a key role in tumor cell proliferation, survival, and angiogenesis, particularly in cancers with FGFR mutations or amplifications. Irpagratinib exhibits potent anti-cancer activity by inhibiting the phosphorylation and activation of FGFR, leading to reduced tumor growth and metastasis. It is being investigated in Cancer Disease Research, with particular focus on solid tumors such as bladder cancer and other FGFR-driven malignancies. This targeted approach aims to improve treatment outcomes with fewer off-target effects compared to conventional chemotherapy.
| CAS Number | 2230974-62-4 |
| Synonyms | N-[(3S,4S)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]oxan-4-yl]prop-2-enamide |
| Molecular Formula | C28H32F2N6O5 |
| Purity | ≥95% |
| IUPAC Name | N-[(3S,4S)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]oxan-4-yl]prop-2-enamide |
| InChI | InChI=1S/C28H32F2N6O5/c1-6-21(37)32-16-7-8-41-12-18(16)34-27-31-11-15-9-17(22-23(29)19(38-3)10-20(39-4)24(22)30)33-26(25(15)35-27)36-13-28(2,14-36)40-5/h6,9-11,16,18H,1,7-8,12-14H2,2-5H3,(H,32,37)(H,31,34,35)/t16-,18+/m0/s1 |
| InChIKey | PGRHEHZIRYNZDV-FUHWJXTLSA-N |
| SMILES | CC1(CN(C1)C2=C3C(=CC(=N2)C4=C(C(=CC(=C4F)OC)OC)F)C=NC(=N3)NC5COCCC5NC(=O)C=C)OC |
